Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients.
about
A multi-scale approach to designing therapeutics for tuberculosisA computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatmentPharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment durationPharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis.Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs.Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variabilityA sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosetsGlobal Urine Metabolomics in Patients Treated with First-Line Tuberculosis Drugs and Identification of a Novel Metabolite of EthambutolPopulation modeling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs.Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi.Isoniazid pharmacokinetics, pharmacodynamics, and dosing in South African infants.Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteersRole of pharmacogenomics in the treatment of tuberculosis: a reviewSerum drug concentrations predictive of pulmonary tuberculosis outcomes.HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended dosesIsoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation.The challenges of pharmacokinetic variability of first-line anti-TB drugs.Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB?Pharmacogenomics for infectious diseases in sub-Saharan Africa: Successes and opportunities.Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial.In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substratesEvidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy.The importance of clinical pharmacokinetic-pharmacodynamic studies in unraveling the determinants of early and late tuberculosis outcomes
P2860
Q28647309-FF83533B-0982-4CA4-9DE9-BD7DDCFD5C95Q28649754-7BF96723-0BDF-46AF-9B1C-8CB0912887F1Q30377051-9EAF2F43-31FF-40FE-BDAD-9094E0CA2D78Q33797850-2F6EBB68-915F-4469-8498-88D67DCD3000Q33843657-BC0BF014-C1E5-41DC-843C-744BB4C959FEQ34922554-822C20C1-1B0E-40C9-B8B7-80FA52954D9EQ35242238-126188F4-1331-4191-9127-D5CE8B2458C1Q35532853-6D3CAAA5-0796-4578-A406-EAD07D12BA9DQ35745991-7B3D17CF-79B9-4232-B796-BC852FEA0B1DQ35911355-0203759D-82C1-4E39-AB68-E9722618C002Q35960852-C49B166F-4F5A-4582-936B-AB5AF2901632Q36075981-5DFF4584-423E-4D75-BFFF-FEA648A520ACQ36097299-80E7DBBD-3DCB-45B6-9173-A19E2EE027AEQ36158322-0161A7EC-33D5-4BBE-B000-0FFAF6DA2F05Q36441540-B15E550E-2E60-4D6B-B98B-8731F7BBB8F0Q37213037-45C3DA4C-ECD0-47EB-BA37-7EF903C44994Q37287701-281CD104-4875-4F73-B247-1BEEF594F7CAQ37688266-E5037A27-717E-49C8-B8CD-FF456089D86DQ38803026-B6E03CFA-6B6C-4D43-8EAC-A5116E2ACF4EQ38977166-BB98EDAA-F217-4298-BD85-D3D4E42FA64AQ40035394-62046909-870A-47CE-B052-AE20E9D54C9CQ40632449-B90C3759-1530-4315-8C07-94807EDABBEFQ40867178-FDE2F909-4483-49AD-9DEA-38E96D22E8F7Q41986948-19993492-3904-4526-BEC5-CCA89137B3CFQ48287062-ED4416DA-9400-462C-92FD-4EED013CE778Q57152709-D0EE4B72-703D-4DC8-B2E1-0ABF559DB2B4
P2860
Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Variability in the population ...... African tuberculosis patients.
@ast
Variability in the population ...... African tuberculosis patients.
@en
type
label
Variability in the population ...... African tuberculosis patients.
@ast
Variability in the population ...... African tuberculosis patients.
@en
prefLabel
Variability in the population ...... African tuberculosis patients.
@ast
Variability in the population ...... African tuberculosis patients.
@en
P2093
P2860
P1476
Variability in the population ...... African tuberculosis patients.
@en
P2093
Goonaseelan Pillai
Grant Langdon
Peter J Smith
Ulrika S H Simonsson
P2860
P356
10.1111/J.1365-2125.2011.03940.X
P407
P577
2011-07-01T00:00:00Z